Which patients with myelofibrosis should receive ruxolitinib therapy?: ELN-SIE evidence-based recommendations
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2017
|
| In: |
Leukemia
Year: 2017, Volume: 31, Issue: 4, Pages: 882-888 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2016.283 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2016.283 Verlag, Volltext: http://www.nature.com/doifinder/10.1038/leu.2016.283 
|
| Author Notes: | M. Marchetti, G. Barosi, F. Cervantes, G. Birgegård, M. Griesshammer, C. Harrison, R. Hehlmann, J.-J. Kiladjian, N. Kröger, M.F. McMullin, F. Passamonti, A. Vannucchi and T. Barbui |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581458908 | ||
| 003 | DE-627 | ||
| 005 | 20220815022823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181001s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/leu.2016.283 |2 doi | |
| 035 | |a (DE-627)1581458908 | ||
| 035 | |a (DE-576)511458908 | ||
| 035 | |a (DE-599)BSZ511458908 | ||
| 035 | |a (OCoLC)1341019332 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Marchetti, Marco |e VerfasserIn |0 (DE-588)1126210536 |0 (DE-627)880830603 |0 (DE-576)48390015X |4 aut | |
| 245 | 1 | 0 | |a Which patients with myelofibrosis should receive ruxolitinib therapy? |b ELN-SIE evidence-based recommendations |c M. Marchetti, G. Barosi, F. Cervantes, G. Birgegård, M. Griesshammer, C. Harrison, R. Hehlmann, J.-J. Kiladjian, N. Kröger, M.F. McMullin, F. Passamonti, A. Vannucchi and T. Barbui |
| 264 | 1 | |c 2017 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published 14 October 2016 | ||
| 500 | |a Gesehen am01.10.2018 | ||
| 700 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 31(2017), 4, Seite 882-888 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations |
| 773 | 1 | 8 | |g volume:31 |g year:2017 |g number:4 |g pages:882-888 |g extent:7 |a Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/leu.2016.283 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.nature.com/doifinder/10.1038/leu.2016.283 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181001 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |e 60000PH1037003489 |k 0/60000/ |p 7 | ||
| 999 | |a KXP-PPN1581458908 |e 3027495755 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["M. Marchetti, G. Barosi, F. Cervantes, G. Birgegård, M. Griesshammer, C. Harrison, R. Hehlmann, J.-J. Kiladjian, N. Kröger, M.F. McMullin, F. Passamonti, A. Vannucchi and T. Barbui"]},"person":[{"given":"Marco","display":"Marchetti, Marco","role":"aut","family":"Marchetti"},{"given":"Rüdiger","display":"Hehlmann, Rüdiger","family":"Hehlmann","role":"aut"}],"recId":"1581458908","note":["Published 14 October 2016","Gesehen am01.10.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"subtitle":" ELN-SIE evidence-based recommendations","title":"Which patients with myelofibrosis should receive ruxolitinib therapy?","title_sort":"Which patients with myelofibrosis should receive ruxolitinib therapy?"}],"physDesc":[{"extent":"7 S."}],"id":{"eki":["1581458908"],"doi":["10.1038/leu.2016.283"]},"relHost":[{"disp":"Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendationsLeukemia","type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"volume":"31","year":"2017","text":"31(2017), 4, Seite 882-888","issue":"4","pages":"882-888","extent":"7"},"language":["eng"],"pubHistory":["Nachgewiesen 11.1997 -"],"note":["Gesehen am 15.03.04"],"id":{"zdb":["2008023-2"],"eki":["32046699X"],"issn":["1476-5551"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title":"Leukemia"}],"origin":[{"publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedKey":"1997","dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group"}],"recId":"32046699X"}],"origin":[{"dateIssuedDisp":"2017","dateIssuedKey":"2017"}]} | ||
| SRT | |a MARCHETTIMWHICHPATIE2017 | ||